Randomized phase 3 trial comparing 2 cisplatin dose schedules in 326 patients with locally advanced squamous cell cervical carcinoma : Long-term follow-up

International Journal of Gynecological Cancer

Volumn 22, Issue 9, 2012, Pages 1538-1544

  Nagy, Viorica Magdalena ^a,b   Ordeanu, Claudia ^a   Coza, Ovidiu ^a,b   Alin, Cristian Rancea ^a,b   Traila, Alexandru ^a   Todor, Nicolae ^a  

^a THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Cervical cancer; Cisplatin; Concomitant radio chemotherapy

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; RADIOTHERAPY, ADJUVANT; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84872288661     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318270590a     Document Type: Article

References (18)

1. GLOBOCAN Cancer Fact Sheet: Cervical Cancer Incidence and Mortality Worldwide in 2008.
2. Haie-Meder C, Fervers B, Fondrinier E, et al. SOR guidelines for concomitant chemoradiotherapy for patients with uterine cervical cancers: evidence update bulletin 2004. Ann Oncol. 2005;16:1100-1108.
3. American College of Obstetricians and Gynecologists. ACOG practice bulletin number 25, May 2002. Diagnosis and treatment of cervical carcinomas. Int J Gynaecol Obstet. 2002;78:79-91.
4. Nagy V, Todor N, Coza O, et al. Quality of life treatment related toxicity in 335 patients with locally advanced cervical carcinoma treated by two chemoradiation regimens. J BUON. 2007;12:389-394.
5. Eifel PJ. Problems with the clinical staging of carcinoma of the cervix. Semin Radiat Oncol. 1994;4:1-8.
6. International Federation of Gynecology and Oncology. Staging announcement. FIGO staging of gynecologic cancers; cervical and vulva. Int J Gynecol Cancer. 1995;5:319.
7. Key HM, Bundy BN, Stehman FB, et al. Cisplatin radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-1161.
8. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340: 1137-1143.
9. Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606-1613.
10. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144-1153.
11. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes. Gynecologic Oncology Group and Southwest Group study. J Clin Oncol. 1999;17:1339-1348.
12. Green JA, Kirwan JM, Tierney JF. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781-786.
13. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005;CD002225.
14. Vale CL. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev. 2010;CD008285.
15. Nagy V, Coza O, Ordeanu C, et al. Radiotherapy versus concurrent 5-day cisplatin and radiotherapy in locally advanced cervical carcinoma. Strahlentherapie und Onkologie. 2009;185:177-183.
16. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based chemoradiation improves progression-free survival in advanced cervical cancer: results of a randomized Gynecologic Oncology Group study. New Engl J Med. 1999;340:1144-1153.
17. Einstein MH, Novetsky AP, Garg M, et al. Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer. Cancer. 2007;109:48-53.
18. Lee HN, Lee KH, Lee DW, et al. Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer. Int J Gynecol Cancer. 2011;21:128-136.